1 Green Flag and 1 Red Flag for Amgen

Amid a gloomier performance from the broader market, the healthcare industry has presented a few bright spots for investors. Amgen (NASDAQ: AMGN), a biotech pioneer that uses living cells to make biologic medicines, has seen its stock rise 10% year-to-date. For context, the S&P 500 has dropped nearly 12% in the same time frame.

Let's look at what's going right for the company and one obstacle it could face.

Image source: Getty Images.

Source Fool.com